Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.55 |
| ▸ | TP53 | P04637 | 3/20 | 0.55 |
| ▸ | CASP3 | P42574 | 2/20 | 0.49 |
| ▸ | MDM2 | Q00987 | 5/20 | 0.49 |
| ▸ | TNF | P01375 | 1/20 | 0.47 |
| ▸ | TLR2 | O60603 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31714219 | 1.00 | MDM4 (0.55) | MDM4TP53CASP3MDM2TNF | |
| SCHEMBL29399025 | 1.00 | MDM4 (0.55) | MDM4TP53CASP3MDM2TNF | |
| SCHEMBL29398330 | 1.00 | MDM4 (0.55) | MDM4TP53CASP3MDM2TNF | |
| SCHEMBL8059732 | 0.92 | MDM2 (0.55) | MDM4TP53CASP3MDM2TNF | |
| SCHEMBL31749819 | 0.92 | MDM2 (0.55) | MDM4TP53CASP3MDM2TNF | |
| SCHEMBL25280271 | 0.92 | MDM2 (0.55) | MDM4TP53CASP3MDM2TNF | |
| SCHEMBL23157053 | 0.91 | MDM4 (0.49) | MDM4TP53CASP3MDM2TLR2 | |
| SCHEMBL119491 | 0.89 | MDM4 (0.54) | MDM4TP53CASP3MDM2TLR2 | |
| SCHEMBL1312329 | 0.89 | MDM4 (0.54) | MDM4TP53CASP3MDM2TLR2 | |
| SCHEMBL30191631 | 0.89 | MDM4 (0.54) | MDM4TP53CASP3MDM2TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250250226-A1 | IONIZABLE COMPOUNDS AND COMPOSITIONS AND USES THEREOF | NITTO DENKO CORP (JP) | 2025-08-07 | — | — | US | disclosed |
| US-12319643-B2 | Ionizable compounds and compositions and uses thereof | NITTO DENKO CORPORATION (JP) | 2025-06-03 | — | — | US | disclosed |
| US-20220242820-A1 | IONIZABLE COMPOUNDS AND COMPOSITIONS AND USES THEREOF | NITTO DENKO CORPORATION (JP) | 2022-08-04 | — | — | US | disclosed |
| US-11384051-B2 | Ionizable compounds and compositions and uses thereof | NITTO DENKO CORPORATION (JP) | 2022-07-12 | — | — | US | disclosed |
| EP-3313449-B1 | IONIZABLE COMPOUNDS AND COMPOSITIONS AND USES THEREOF | NITTO DENKO CORP (JP) | 2020-09-23 | — | — | EP | disclosed |
| EP-3686184-A2 | IONIZABLE COMPOUNDS AND COMPOSITIONS AND USES THEREOF | NITTO DENKO CORPORATION (JP) | 2020-07-29 | — | — | EP | disclosed |
| US-20190127318-A1 | IONIZABLE COMPOUNDS AND COMPOSITIONS AND USES THEREOF | NITTO DENKO CORPORATION (JP) | 2019-05-02 | — | — | US | disclosed |
| US-10167253-B2 | Ionizable compounds and compositions and uses thereof | NITTO DENKO CORPORATION (JP) | 2019-01-01 | — | — | US | disclosed |
| US-20160376229-A1 | IONIZABLE COMPOUNDS AND COMPOSITIONS AND USES THEREOF | NITTO DENKO CORPORATION (JP) | 2016-12-29 | — | — | US | disclosed |
| US-9409952-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-08-09 | — | — | US | disclosed |
| US-9409952-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-08-09 | — | — | US | disclosed |
| US-20160021882-A1 | APPLICATION OF BIOFILM FORMATION INHIBITING COMPOUNDS ENHANCES CONTROL OF CITRUS CANKER | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2016-01-28 | — | — | US | disclosed |
| US-20160021882-A1 | APPLICATION OF BIOFILM FORMATION INHIBITING COMPOUNDS ENHANCES CONTROL OF CITRUS CANKER | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2016-01-28 | — | — | US | disclosed |
| CN-101146545-B | Mucin hypersecretion inhibitors based on the structure of MANS and methods of use | BIOMARCK PHARMACEUTICALS LTD | 2012-12-26 | — | — | CN | disclosed |
| CN-101146545-A | Mucin hypersecretion inhibitors based on the structure of MANS and methods of use | BIOMARCK PHARMACEUTICALS LTD (US) | 2008-03-19 | — | — | CN | disclosed |
| EP-0989136-A1 | PEPTIDES HAVING CYCLIC STRUCTURES AND EXERTING P53 PROTEIN ACTIVTY-RESTORING EFFECT ON P53 PROTEIN MUTANTS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2000-03-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220242820-A1 | IONIZABLE COMPOUNDS AND COMPOSITIONS AND USES THEREOF | NCL, RNASE1, RNMT | MDM4 2176/4885TP53 97/4885CASP3 1459/4885 |
| US-20250250226-A1 | IONIZABLE COMPOUNDS AND COMPOSITIONS AND USES THEREOF | NCL, RNASE1, RNMT | MDM4 2176/4885TP53 97/4885CASP3 1459/4885 |
| US-10167253-B2 | Ionizable compounds and compositions and uses thereof | NCL, CHMP4B, RNASE1 | MDM4 1986/4885TP53 263/4885CASP3 2028/4885 |
| US-20160376229-A1 | IONIZABLE COMPOUNDS AND COMPOSITIONS AND USES THEREOF | NCL, CHMP4B, RNASE1 | MDM4 1986/4885TP53 263/4885CASP3 2028/4885 |
| US-11384051-B2 | Ionizable compounds and compositions and uses thereof | NCL, CHMP4B, RNASE1 | MDM4 1986/4885TP53 263/4885CASP3 2028/4885 |
| US-20190127318-A1 | IONIZABLE COMPOUNDS AND COMPOSITIONS AND USES THEREOF | NCL, CHMP4B, RNASE1 | MDM4 1986/4885TP53 263/4885CASP3 2028/4885 |
| US-12319643-B2 | Ionizable compounds and compositions and uses thereof | NCL, RNASE1, RNMT | MDM4 2176/4885TP53 97/4885CASP3 1459/4885 |
| US-20160021882-A1 | APPLICATION OF BIOFILM FORMATION INHIBITING COMPOUNDS ENHANCES CONTROL OF CITRUS CANKER | XDH, MYB, DDC | MDM4 2572/4885TP53 4486/4885CASP3 801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.